Intuitive Surgical (ISRG) — Q3 2026 Earnings Preview
Key Factors to Watch for Q3 2026
| Factor | Details & Context |
|---|---|
| Revenue Growth | Consensus: $2,908M (+3% QoQ, +16% YoY); watch for impact of U.S. procedure moderation and OUS strength. |
| Gross Profit Margin | Consensus: 68.1%; guidance range: 68–69%; monitor for mix effects (da Vinci 5, XiR, SP, Ion) and cost trends. |
| Procedure Growth | Guidance: 13.5–15.5% for FY26 (midpoint expected); Q2 actual: +16% total, +15% da Vinci, +36% Ion. |
| U.S. Procedure Trends | Q2: +12% da Vinci; management flagged ACA subsidy expiration and law of large numbers as headwinds. |
| OUS Procedure Trends | Q2: +20% da Vinci; strong in India, Italy, Taiwan, UK; China/Japan slightly above global average but still challenged. |
| Extended Use Program Impact | Launching H1 2027; no quantification yet, but expected to lower I&A per procedure and stimulate volume in cost-sensitive segments. |
| Capital Equipment Demand | Q2: U.S. placements +24% YoY, OUS +12% YoY; watch for any signs of capital cycle softening or shifts in leasing vs. purchase. |
| Mix/Portfolio Dynamics | XiR placements rising (64 in Q2), especially in ASCs and cost-constrained OUS markets; da Vinci 5 upgrades remain strong. |
| Operating Margin | Q2: 42% non-GAAP; company notes room to invest in innovation, but margin may moderate with higher R&D. |
| Guidance Updates | Any revision to FY26 procedure growth, margin, or OpEx guidance; quantification of extended use program impact expected Q3 call. |
Summary and Conclusions
- Intuitive Surgical enters Q3 2026 with solid momentum but faces a tougher U.S. comparable and some macro headwinds.
- Q2 2026 saw revenue of $2,825M (+19% YoY), gross margin of 67.7%, and operating margin of 42%.
- U.S. da Vinci procedure growth moderated to +12% (from +14% in Q1), with management citing ACA subsidy expiration and law of large numbers.
- OUS growth remains robust at +20% da Vinci, with particular strength in India, Italy, Taiwan, and the UK.
- Ion platform continues to outperform, with +36% procedure growth in Q2.
- Consensus expects Q3 2026 revenue of $2,908M and gross margin of 68.1%.
- Guidance for FY26 da Vinci procedure growth is 13.5–15.5%, with management expecting results near the midpoint.
- Gross margin guidance was raised to 68–69% (from 67.5–68.5%) on Q2 call, reflecting product cost reductions and tariff refunds.
- Key watch items for the print:
- Whether U.S. procedure growth stabilizes or further decelerates.
- OUS momentum, especially in Japan (new reimbursement) and China (policy/tender clarity expected in 2027).
- Uptake of XiR in ASCs and cost-sensitive OUS markets.
- Early customer feedback and renewal rates for My Intuitive+ digital subscriptions.
- Any quantification or early commentary on the impact of the extended use program for EndoWrist instruments (to launch H1 2027).
- Management’s tone on competitive dynamics, especially with new entrants (e.g., Medtronic OTTAVA, Cornerstone JV).
- Last year’s Q3 (2025) was a very strong quarter, creating a tough YoY comp:
- Q3 2025 revenue: $2,412M (+23% YoY), procedure growth: +20%, da Vinci procedures: +19%, Ion: +52%.
- Q3 2025 gross margin: 68% (pro forma), operating margin: 39%, EPS: $2.40 (pro forma).
- Q3 2025 benefited from the broad launch of da Vinci 5 and strong U.S. and OUS demand.
Quarterly Financial Snapshot — Actuals and Consensus
Quarterly Income Statement (Q3 2025–Q4 2026, $M)
| Quarter | Revenue | Gross Profit Margin (%) | EBITDA | Net Income | EPS (GAAP) |
|---|---|---|---|---|---|
| Q4 2026E | 3,213 | 68.1 | 1,471 | 1,014 | 2.54 |
| Q3 2026E | 2,908 | 68.1 | 1,315 | 940 | 2.37 |
| Q2 2026A | 2,825 | 67.7 | 1,266 | 897 | 2.15 |
| Q1 2026A | 2,618 | 66.1 | 1,057 | 761 | 1.93 |
| Q4 2025A | 2,765 | 66.9 | 1,149 | 818 | 1.95 |
| Q3 2025A | 2,412 | 66.0 | 990 | 718 | 1.70 |
*E = consensus estimate; A = actual
Full-Year Financial Snapshot — Actuals and Consensus
| Fiscal Year | Revenue | Gross Profit Margin (%) | EBITDA | Net Income | EPS (GAAP) |
|---|---|---|---|---|---|
| 2026E | 11,757 | 68.4 | 5,327 | 3,856 | 9.23 |
| 2025A | 9,948 | 67.3 | 4,282 | 3,141 | 7.44 |
| 2024A | 8,180 | 68.5 | 3,355 | 2,498 | 5.95 |
Procedure Growth and Guidance
| Period | Da Vinci Procedure Growth (YoY) | Ion Procedure Growth (YoY) | Total Procedure Growth (YoY) | Guidance/Notes |
|---|---|---|---|---|
| Q2 2026 | +15% | +36% | +16% | Guidance: 13.5–15.5% for FY26, midpoint expected |
| Q1 2026 | +16% | +39% | +17% | |
| Q4 2025 | +17% | +44% | +18% | |
| FY 2025 | +18% | +51% | +19% | |
| Q3 2025 | +19% | +52% | +20% | Tough comp for Q3 2026 |
Guidance Summary — FY 2026 (as of Q2 2026)
| Metric | Guidance (FY 2026) | Latest Update (Q2 2026) | Notes |
|---|---|---|---|
| Da Vinci Procedure Growth | 13.5–15.5% | Maintained, midpoint expected | Primary drivers: U.S. general surgery, OUS non-urology; ACA, China, Japan as risks |
| Non-GAAP Gross Margin | 68–69% | Raised from 67.5–68.5% | Reflects cost reductions, tariff refund, higher input costs (freight, semiconductors) |
| Non-GAAP OpEx Growth | 11–13% | Lowered from 11–14% | R&D growing faster than SG&A; no Foundation contribution in 2026 |
| Stock Comp Expense | $880M–$900M | Narrowed from $890M–$920M | |
| Other Income | $315M–$335M | Lowered from $355M–$375M | Lower cash balances post-buybacks |
| Non-GAAP Tax Rate | 22–23% | Unchanged |
What Changed / Incremental Developments
- Extended Use Program: Announced for H1 2027, targeting cost-sensitive benign procedures and geographies. Quantification of impact to be provided on Q3 call. Expected to lower I&A per procedure and stimulate volume elasticity.
- XiR Momentum: XiR placements rising, especially in ASCs (27 in Q2, 20 of which were XiR) and OUS cost-constrained markets. Installed base ~130 after one year.
- My Intuitive+ Renewals: First wave of renewals in Q2; no customers opted out. List price $40,000/system/year; impact on service revenue line.
- Japan Reimbursement: New policies effective June 2026, including reimbursement for additional procedures (largest: inguinal hernia). Impact expected to build into 2027.
- China Policy Environment: Centralized tender process and new charge codes expected to bring clarity in 2027; current placements muted, high utilization constraining capacity for growth.
- Competitive Landscape: New entrants (Medtronic OTTAVA, Cornerstone JV) noted; management emphasizes full ecosystem, software, and AI as differentiators.
Management Commentary Highlights
- On U.S. Procedure Growth: Management acknowledges deceleration due to ACA subsidy expiration and law of large numbers, but sees significant opportunity in benign general surgery and new procedures (cardiac, NSM).
- On OUS Growth: OUS remains a strategic focus, with segmentation (XiR, X, da Vinci 5) enabling penetration in both premium and cost-constrained markets.
- On Capital Demand: U.S. capital environment stable; 70–75% of systems leased, providing flexibility. OUS capital more mixed, with some markets under budget pressure.
- On Innovation and Margins: Strong financial performance above long-term averages attributed to innovation (da Vinci 5, SP, Ion, digital/AI). Operating margin at 41% in H1 2026 provides room for investment.
- On Extended Use Program: Strategy is to lower total cost to treat, drive elasticity in cost-sensitive segments, and reinforce the virtuous cycle of adoption and scale.
Conclusion
Intuitive Surgical heads into Q3 2026 with continued global adoption, but faces a tougher U.S. comparable and macro headwinds (ACA, China, Japan). The company’s innovation pipeline (da Vinci 5, XiR, SP, Ion, digital/AI) and segmentation strategy are driving above-average financial performance, but investors should closely watch for stabilization in U.S. procedure growth, OUS momentum, and any quantification of the extended use program’s impact. Management’s tone remains confident in the long-term opportunity and ability to compete, but near-term focus will be on execution against guidance and navigating evolving market dynamics.
